KRW 23050.0
(-1.5%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 135.95 Billion KRW | 26.49% |
2022 | 107.48 Billion KRW | 71.01% |
2021 | 62.85 Billion KRW | 54.92% |
2020 | 40.57 Billion KRW | 12.39% |
2019 | 36.09 Billion KRW | 75.75% |
2018 | 20.54 Billion KRW | 32.03% |
2017 | 15.55 Billion KRW | -23.54% |
2016 | 20.34 Billion KRW | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 33.45 Billion KRW | -0.78% |
2024 Q2 | 35.77 Billion KRW | 6.94% |
2023 Q3 | 34.63 Billion KRW | -1.62% |
2023 FY | 135.95 Billion KRW | 26.49% |
2023 Q4 | 33.71 Billion KRW | -2.66% |
2023 Q2 | 35.2 Billion KRW | 8.67% |
2023 Q1 | 32.39 Billion KRW | -19.24% |
2022 FY | 107.48 Billion KRW | 71.01% |
2022 Q1 | 20.07 Billion KRW | 14.03% |
2022 Q4 | 40.11 Billion KRW | 59.76% |
2022 Q3 | 25.11 Billion KRW | 13.21% |
2022 Q2 | 22.18 Billion KRW | 10.49% |
2021 Q3 | 17.1 Billion KRW | 0.0% |
2021 FY | 62.85 Billion KRW | 54.92% |
2021 Q4 | 17.6 Billion KRW | 2.91% |
2020 FY | 40.57 Billion KRW | 12.39% |
2019 FY | 36.09 Billion KRW | 75.75% |
2018 FY | 20.54 Billion KRW | 32.03% |
2017 FY | 15.55 Billion KRW | -23.54% |
2016 FY | 20.34 Billion KRW | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
CMG Pharmaceutical Co., Ltd. | 93.9 Billion KRW | -44.774% |
Celltrion Pharm, Inc. | 388.79 Billion KRW | 65.032% |
Huons Global Co., Ltd. | 758.37 Billion KRW | 82.073% |
DongKook Pharmaceutical Co., Ltd. | 730.99 Billion KRW | 81.402% |
Enzychem Lifesciences Corporation | 76.03 Billion KRW | -78.794% |
Humedix Co., Ltd. | 152.27 Billion KRW | 10.718% |
Boditech Med Inc. | 134.21 Billion KRW | -1.292% |
EuBiologics Co., Ltd. | 69.36 Billion KRW | -95.994% |
FutureChem Co.,Ltd | 13.96 Billion KRW | -873.315% |
Huons Co., Ltd. | 552 Billion KRW | 75.371% |
BNC Korea Co., Ltd. | 80.99 Billion KRW | -67.848% |
AptaBio Therapeutics Inc. | 323.86 Million KRW | -41877.723% |